Ezetimibe reduces α-tocopherol levels in type 2 diabetes.

Area of Science:

• Endocrinology
• Nutritional Science
• Pharmacology

Background:

• Alpha-tocopherol (vitamin E) protects against free radical damage.
• Niemann-Pick C1-like 1 (NPC1L1) protein facilitates intestinal absorption of alpha-tocopherol.
• Ezetimibe targets NPC1L1 and is commonly prescribed for hypercholesterolemia, often with statins, in type 2 diabetes patients.

Purpose of the Study:

• To investigate the impact of ezetimibe treatment on plasma alpha-tocopherol levels in patients with type 2 diabetes.
• To determine if ezetimibe influences the blood concentration of alpha-tocopherol.

Main Methods:

• Recruited 200 type 2 diabetes patients not taking vitamin supplements.
• Measured alpha-tocopherol using high-performance liquid chromatography (HPLC).
• Utilized linear multivariate regression to analyze factors associated with alpha-tocopherol levels, comparing ezetimibe users and non-users.

Main Results:

• Patients on ezetimibe exhibited significantly lower mean plasma alpha-tocopherol levels (29.9 ± 5.7 μmol/L) compared to non-users (32.9 ± 7.0 μmol/L; p=0.006).
• Ezetimibe treatment showed a significant negative association with alpha-tocopherol levels in multivariate analysis (β = -0.217, p = 0.002).

Conclusions:

• Ezetimibe treatment can decrease plasma alpha-tocopherol levels.
• This reduction is likely due to ezetimibe's inhibition of the NPC1L1 protein, which is crucial for alpha-tocopherol absorption.
• Further research is needed to understand the clinical significance of reduced alpha-tocopherol in patients taking ezetimibe.